4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
MedKoo(授权代理)
主营:主营:抗癌化学试剂和激酶抑制剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > peptide > MedKoo/9-hydroxyellipticine HClfeatured/100mg/406583
商品详细MedKoo/9-hydroxyellipticine HClfeatured/100mg/406583
MedKoo/9-hydroxyellipticine HClfeatured/100mg/406583
MedKoo/9-hydroxyellipticine HClfeatured/100mg/406583
商品编号: 406583
品牌: MedKoo
市场价: ¥25000.00
美元价: 15000.00
产地: 美国(厂家直采)
公司:
产品分类: 多肽合成
公司分类: peptide
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

9-hydroxyellipticine HCl
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:406583

CAS#:52238-35-4 (HCl)

Description:9-hydroxyellipticine, also known asIGIG 929 and LS133324, is a potent cytotoxic and antitumor agent. Structurally, 9-hydroxyellipticine is a 9-hydroxy derivative of ellipticine. The hydroxy group in 9-hydroxyellipticines increases the apparent affinity for DNA, stabilisation of toposiomerase II-DNA cleavable complex, oxidation to reactive quinone-imine intermediates, phosphorylation of p53 suppressor proteins and cytotoxicity relative to the parent ellipticines.

Price and Availability

SizePriceShipping out timeQuantity
100mgUSD 12502 Weeks
200mgUSD 19502 Weeks
500mgUSD 24502 Weeks
1gUSD 32502 Weeks
2gUSD 46502 Weeks
5gUSD 72502 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

9-hydroxyellipticine, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406583Name: 9-hydroxyellipticine HClCAS#: 52238-35-4 (HCl)Chemical Formula: C17H14N2OExact Mass: 262.11061Molecular Weight: 262.31Elemental Analysis:C, 68.34; H, 5.06; Cl, 11.87; N, 9.38; O, 5.35

Related CAS #:51131-85-2 (free base)52238-35-4 (HCl)58447-24-8 (methiodide).

Synonym:9-hydroxyellipticine HCl; 9-hydroxyellipticine hydrochloride; Hydroxyellipticine; 9-Hydroxyellipticin; NSC 210717;IGIG 929; IGIG929; IGIG-929; LS133324; LS-133324; LS 133324.

IUPAC/Chemical Name:5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-ol hydrochloride

InChi Key:DLDKVFOKLGPVBT-UHFFFAOYSA-N

InChi Code:InChI=1S/C17H14N2O.ClH/c1-9-14-8-18-6-5-12(14)10(2)17-16(9)13-7-11(20)3-4-15(13)19-17;/h3-8,19-20H,1-2H3;1H

SMILES Code:OC1=CC2=C(NC3=C2C(C)=C(C=NC=C4)C4=C3C)C=C1.[H]Cl

Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

References

1: Harding MM, Grummitt AR. 9-hydroxyellipticine andderivatives as chemotherapy agents. Mini Rev Med Chem. 2003Mar;3(2):67-76. Review. PubMed PMID: 12570841.

2: Saeki K, Obi I, Ogiku N, Shigekawa M, Imagawa T, Matsumoto T.Cardioprotective effects of 9-hydroxyellipticine on ischemia andreperfusion in isolated rat heart. Jpn J Pharmacol. 2002 May;89(1):21-8.PubMed PMID: 12083739.

3: Sugikawa E, Tsunoda S, Nakanishi N, Ohashi M. 9-Hydroxyellipticinealters the conformation and DNA binding characteristics of mutated p53protein. Anticancer Res. 2001 Jul-Aug;21(4A):2671-5. PubMed PMID:11724337.

4: Mizumoto K, Sato N, Kusumoto M, Niiyama H, Maehara N, Nishio S, Li Z,Ogawa T, Tanaka M. Diverse effects of 9-hydroxyellipticine on thechemosensitivity of human pancreatic cancer cells harboring p53mutations. Cancer Lett. 2000 Feb 28;149(1-2):85-94. PubMed PMID:10737712.

5: Sugikawa E, Hosoi T, Yazaki N, Gamanuma M, Nakanishi N, Ohashi M.Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1phase by 9-hydroxyellipticine. Anticancer Res. 1999Jul-Aug;19(4B):3099-108. PubMed PMID: 10652599.

6: Khélifa T, René B, Le Mée S, Lambert B, Saucier JM, Markovits J,Jacquemin-Sablon H, Jacquemin-Sablon A. Transfection of9-hydroxyellipticine-resistant Chinese hamster fibroblasts with humantopoisomerase IIalpha cDNA: selective restoration of the sensitivity toDNA religation inhibitors. Cancer Res. 1999 Oct 1;59(19):4927-36. PubMedPMID: 10519406.

7: Sato N, Mizumoto K, Kusumoto M, Niiyama H, Maehara N, Ogawa T, TanakaM. 9-Hydroxyellipticine inhibits telomerase activity in human pancreaticcancer cells. FEBS Lett. 1998 Dec 18;441(2):318-21. PubMed PMID:9883907.

8: Ismail MA, Sanders KJ, Fennell GC, Latham HC, Wormell P, Rodger A.Spectroscopic studies of 9-hydroxyellipticine binding to DNA.Biopolymers. 1998 Sep;46(3):127-43. PubMed PMID: 9741963.

9: Elcock AH, Rodger A, Richards WG. Theoretical studies of theintercalation of 9-hydroxyellipticine in DNA. Biopolymers. 1996Sep;39(3):309-26. PubMed PMID: 8756512.

10: Ohashi M, Sugikawa E, Nakanishi N. Inhibition of p53 proteinphosphorylation by 9-hydroxyellipticine: a possible anticancermechanism. Jpn J Cancer Res. 1995 Sep;86(9):819-27. PubMed PMID:7591958.

品牌介绍
MedKoo 美帝药库公司以药物化学合成技术为核心,密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向,不断推出抗癌化合物新品种。 。 美帝药库MedKoo将在中国建立药物化学合成生产基地和多个现代化药物化合物存储仓库。 美帝药库的药物化合物来源于以下几个渠道:自主合成、委托化学合成、合作伙伴、和从国内外市场上选购。 MedKoo美帝药库的抗癌分子库 MedKoo的目标是打造全球规模最大、品种最多、类别最全和质量最好的小分子抗癌化合物库。MedKoo的抗癌药库将由下列5个分子库组成: (1)上市抗癌药库:该库将含有大约100个全球已批准上市的小分子抗癌化合物; (2)抗癌候选药物库:该分子库含有大约400个世界各国正在临床研究中抗癌小分子候选药物; (3)同系抗癌分子库:该分子库将含有多个化学结构类似或抗癌机制类似的分子包; (4)抗癌分子预制模块库:该库主要含有用于组建抗癌目标分子的分子模块包; (5)同位素标记抗癌分子库。